We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.06B
AUM Growth
+$329M
Cap. Flow
-$217M
Cap. Flow %
-5.35%
Top 10 Hldgs %
37.39%
Holding
124
New
4
Increased
35
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$16.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.8M
4
BPMC
Blueprint Medicines
BPMC
+$12.7M
5
IMVT icon
Immunovant
IMVT
+$12.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$84.9M
2
HUM icon
Humana
HUM
+$62.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.6M
4
ABCM
Abcam PLC
ABCM
+$28.9M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.98%
2 Consumer Staples 1.41%
3 Industrials 1.03%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWAV
51
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$22.9M 0.56%
120,000
-27,500
-19% -$5.2M
PRTA icon
52
Prothena Corp
PRTA
$468M
$22.7M 0.56%
625,048
+10,750
+2% +$414K
IMGN
53
DELISTED
Immunogen Inc
IMGN
$22.5M 0.55%
759,365
– –
NVRO
54
DELISTED
NEVRO CORP.
NVRO
$22.1M 0.54%
1,025,000
-186,600
-15% -$3.33M
AMGN icon
55
Amgen
AMGN
$226B
$21.5M 0.53%
74,500
+6,500
+10% +$1.77M
IRON icon
56
Disc Medicine
IRON
$3.01B
$21M 0.52%
363,468
– –
RVMD icon
57
Revolution Medicines
RVMD
$44.4B
$20.8M 0.51%
725,152
– –
INSP icon
58
Inspire Medical Systems
INSP
$1.73B
$20.1M 0.5%
99,000
+54,500
+122% +$8.83M
IMTX icon
59
Immatics
IMTX
$1.33B
$19.7M 0.49%
1,875,466
– –
BCRX icon
60
BioCryst Pharmaceuticals
BCRX
$2.51B
$19.6M 0.48%
3,270,381
+719,155
+28% +$4.17M
MREO
61
Mereo BioPharma
MREO
$43.5M
$18.4M 0.45%
7,983,851
+307,370
+4% +$588K
COLL icon
62
Collegium Pharmaceutical
COLL
$882M
$17.3M 0.43%
562,000
– –
INZY
63
DELISTED
Inozyme Pharma
INZY
$15.7M 0.39%
3,681,174
– –
FOLD
64
DELISTED
Amicus Therapeutics
FOLD
$15.1M 0.37%
1,063,806
– –
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$13.3B
$14.4M 0.35%
148,832
-115,668
-44% -$10.2M
ICVX
66
DELISTED
Icosavax, Inc. Common Stock
ICVX
$13.7M 0.34%
868,409
– –
KRYS icon
67
Krystal Biotech
KRYS
$9.81B
$12.9M 0.32%
103,969
+13,409
+15% +$1.49M
GPCR icon
68
Structure Therapeutics
GPCR
$3.82B
$11.7M 0.29%
+286,676
New +$16.4M
INBX
69
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
$11.5M 0.28%
+301,400
New +$6.46M
MGNX icon
70
MacroGenics
MGNX
$259M
$11.3M 0.28%
1,178,796
– –
MLYS icon
71
Mineralys Therapeutics
MLYS
$2.41B
$10M 0.25%
1,167,492
– –
ABOS icon
72
Acumen Pharmaceuticals
ABOS
$176M
$8.83M 0.22%
2,300,059
-512,520
-18% -$1.52M
CMPX icon
73
Compass Therapeutics
CMPX
$400M
$8.6M 0.21%
5,513,788
– –
LUNG icon
74
Pulmonx
LUNG
$97.9M
$8.32M 0.2%
652,400
– –
AMLX icon
75
Amylyx Pharmaceuticals
AMLX
$2.53B
$7.88M 0.19%
535,012
-1,010,004
-65% -$15.5M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rock Springs Capital Management held 124 positions worth $4.06B, up 8.8% from $3.73B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $217M in Q4 2023, closing 20 positions and reducing 29 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Eli Lilly worth $40.5M.

  • Rock Springs Capital Management's largest Q4 2023 buy was Eli Lilly: 69,500 shares worth $40.5M.
  • Rock Springs Capital Management added most to Celldex Therapeutics in Q4 2023, an estimated $13.8M increase.
  • Rock Springs Capital Management's biggest Q4 2023 reduction was Humana, cutting an estimated $62.4M.
  • Rock Springs Capital Management fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $84.9M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $4.06B portfolio in Q4 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 20 in Q4 2023.
  • Rock Springs Capital Management's portfolio value rose 8.8% quarter-over-quarter to $4.06B.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.